Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Le-Qun SU"'
Autor:
Qian Li, Yue-E Wu, Kai Wang, Hai-Yan Shi, Yue Zhou, Yi Zheng, Guo-Xiang Hao, Yi-Lei Yang, Le-Qun Su, Wen-Qi Wang, Xin-Mei Yang, Wei Zhao
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Objective: The elucidation of CYP2D6 developmental pharmacogenetics in children has improved, however, these findings have been largely limited to studies of Caucasian children. Given the clear differences in CYP2D6 pharmacogenetic profiles in people
Externí odkaz:
https://doaj.org/article/43a25d8b9d0446b79191265f7e33ceae
Publikováno v:
Endocrine Connections, Vol 8, Iss 4, Pp 318-325 (2019)
Aims: To investigate the difference in the efficacy among dipeptidyl peptidase-4 (DPP-4) inhibitors in Chinese adults with newly diagnosed diabetes. Materials and methods: In a multicenter, randomized study, we enrolled adults who were either treatm
Externí odkaz:
https://doaj.org/article/2a7da67272c84bd088bc45e9714209d3
Autor:
Shu-Xian LYU, Dong-Fang QIAN, Yu-Fei FENG, Cheng-Wu SHEN, Lu-Bo GUO, Jian-Tao LYU, Peng-Fei JIN, Ting LI, Si-Yuan TAN, Zi-Xuan ZHANG, Lin HUANG, Xue ZHONG, Le-Qun SU, Xin HU, Xin HUANG, Xue-Yan CUI
Publikováno v:
J Geriatr Cardiol
BACKGROUND: Butylphthalide (NBP) and edaravone (EDV) injection are common acute ischemic stroke medications in China, but there is a lack of large real-world safety studies on them. This study aimed to determine the incidence of adverse events, detec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d9257ce1bbfd72a1a9daa41bbb2c1a5
https://europepmc.org/articles/PMC10139928/
https://europepmc.org/articles/PMC10139928/
Autor:
Wen-Qi Wang, Bo-Hao Tang, Min Kan, Guo-Xiang Hao, Wei Zhao, Bin Du, Xi-Ting Liu, Yue Zhou, Xin Huang, Pan-Pan Ye, Yi Zheng, Feng Yu, Le-Qun Su
Publikováno v:
Xenobiotica. 50:1275-1284
First dose prediction is challenging in neonates. Our objective in this proof-of-concept study was to perform a pharmacokinetic (PK) bridging study from juvenile mice to neonates for drugs metabolized by CYP3A. We selected midazolam and clindamycin a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4639ce65ec0d0aff27ff42fa37764b79
https://doi.org/10.1080/00498254.2020.1768454
https://doi.org/10.1080/00498254.2020.1768454
Autor:
Guo-Xiang Hao, Xiaoling Wang, Xin-Mei Yang, Wei Zhao, Yi Zheng, Kai Wang, Yi-Lei Yang, Hai-Yan Shi, Min Kan, Le-Qun Su, Qian Li, Yue-E Wu, Evelyne Jacqz-Aigrain, Yue Zhou, Jun Zhou
Publikováno v:
Drug Design, Development and Therapy. 13:4405-4411
Background Montelukast, a potent oral selective leukotriene-receptor antagonist, inhibits the action of cysteinyl-leukotriene in patients with asthma. Although pharmacokinetic studies of montelukast have been reported in Caucasian adults and children
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::091fda721b6de0076921ed543fb6683b
https://doi.org/10.2147/dddt.s226913
https://doi.org/10.2147/dddt.s226913
Autor:
Yi Zheng, Meng Wang, Xi-Ting Liu, Pan-Pan Ye, Rui Yin, Xin-Mei Yang, Bin Du, Lin-Lin Song, Su-Ying Wu, Wen-Qi Wang, Min Kan, Yue Zhou, Bo-Hao Tang, Xin Huang, John N. van den Anker, Le-Qun Su, Wei Zhao, Guo-Xiang Hao, Ai-Qing Nie
Publikováno v:
Journal of Inflammation Research
Yi Zheng,1 Pan-Pan Ye,2 Yue Zhou,1 Su-Ying Wu,3 Xi-Ting Liu,1 Bin Du,1 Bo-Hao Tang,1 Min Kan,1 Ai-Qing Nie,1 Rui Yin,1 Meng Wang,1 Guo-Xiang Hao,1 Lin-Lin Song,2 Xin-Mei Yang,2 Xin Huang,2 Le-Qun Su,2 Wen-Qi Wang,2 John van den Anker,4â 6 Wei Zh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be39f0329de4b27012259941e09784f5
https://www.dovepress.com/lps-induced-inflammation-affects-midazolam-clearance-in-juvenile-mice--peer-reviewed-fulltext-article-JIR
https://www.dovepress.com/lps-induced-inflammation-affects-midazolam-clearance-in-juvenile-mice--peer-reviewed-fulltext-article-JIR
Publikováno v:
Endocrine Connections, Vol 8, Iss 4, Pp 318-325 (2019)
Endocrine Connections
Endocrine Connections
Aims To investigate the difference in the efficacy among dipeptidyl peptidase-4 (DPP-4) inhibitors in Chinese adults with newly diagnosed diabetes. Materials and methods In a multicenter, randomized study, we enrolled adults who were either treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2dc67183b9cf561e7eb11dcb7f2227e2
https://ec.bioscientifica.com/view/journals/ec/8/4/EC-18-0523.xml
https://ec.bioscientifica.com/view/journals/ec/8/4/EC-18-0523.xml
Autor:
Yue-E Wu, Min Kan, Yi Zheng, Hai-Yan Shi, Ling Wu, Xin Huang, Le-Qun Su, Wei Zhao, Guo-Xiang Hao, Yong-Fang Jiang, Xin-Wei Zhou
Publikováno v:
Therapeutic drug monitoring. 42(5)
BACKGROUND Cefotiam, a second-generation cephalosporin, is a broad-spectrum antibiotic with good antibacterial action against both gram-negative and gram-positive bacteria. It is used widely in clinical practice, although bacterial drug resistance ma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2ff58395576c0c4bff83b4f6ea496db
https://pubmed.ncbi.nlm.nih.gov/32251152
https://pubmed.ncbi.nlm.nih.gov/32251152
Autor:
Xue Li, Wei Zhao, Le-Qun Su, Yue-E Wu, Kai Wang, Yi Zheng, Baoping Xu, Bin Du, Rong-Hua Wang, Adong Shen, Hai-Yan Shi, Evelyne Jacqz-Aigrain, Xin Huang, Bo-Hao Tang, Min Kan
Publikováno v:
The Journal of antimicrobial chemotherapy. 75(7)
ObjectivesTo evaluate the population pharmacokinetics of cefoperazone in children and establish an evidence-based dosing regimen using a developmental pharmacokinetic–pharmacodynamic approach in order to optimize cefoperazone treatment.MethodsA mod
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46fc296ba05bbba44c4df6109ef6c576
https://pubmed.ncbi.nlm.nih.gov/32129861
https://pubmed.ncbi.nlm.nih.gov/32129861
Autor:
Qian, Li, Kai, Wang, Hai-Yan, Shi, Yue-E, Wu, Yue, Zhou, Min, Kan, Yi, Zheng, Guo-Xiang, Hao, Xin-Mei, Yang, Yi-Lei, Yang, Le-Qun, Su, Xiao-Ling, Wang, Evelyne, Jacqz-Aigrain, Jun, Zhou, Wei, Zhao
Publikováno v:
Drug Design, Development and Therapy
Background Montelukast, a potent oral selective leukotriene-receptor antagonist, inhibits the action of cysteinyl-leukotriene in patients with asthma. Although pharmacokinetic studies of montelukast have been reported in Caucasian adults and children
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::040d783b1d55f50f40032f7dba15a5d9
https://pubmed.ncbi.nlm.nih.gov/31920289
https://pubmed.ncbi.nlm.nih.gov/31920289